[Role of CD47 in hematologic malignancies]

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• CD47 is a ubiquitous transmembrane glycoprotein involved in immune regulation.
• Its interaction with SIRPα on phagocytic cells transmits inhibitory signals.
• CD47-SIRPα signaling impacts inflammatory, immune, and tumor immunity.

Purpose of the Study:

• To review the structure and immunoregulatory functions of CD47.
• To explore CD47's role in tumor therapy.
• To discuss CD47's involvement in hematologic malignancies and stem cell transplantation.

Main Methods:

• Literature review of CD47's structure and function.
• Analysis of CD47-SIRPα signaling pathways.
• Synthesis of current research on CD47 in hematologic diseases and cancer therapy.

Main Results:

• CD47-SIRPα signaling is a key regulator of immune cell interactions.
• Dysregulation of CD47 contributes to the pathogenesis of hematologic malignancies.
• CD47 blockade is a promising therapeutic approach in oncology and transplantation.

Conclusions:

• CD47 plays a critical role in immune evasion and pathogenesis of hematologic diseases.
• Targeting the CD47-SIRPα axis presents a viable therapeutic strategy.
• Further research is warranted to optimize CD47-based therapies for various conditions.